- Home
- NLSP vs PRPO Comparison
NLSP vs PRPO Comparison
Compare NLSP & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- PRPO
- Stock Information
- Founded
- NLSP 2015
- PRPO N/A
- Country
- NLSP Switzerland
- PRPO United States
- Employees
- NLSP N/A
- PRPO 57
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- NLSP Health Care
- PRPO Industrials
- Exchange
- NLSP Nasdaq
- PRPO Nasdaq
- Market Cap
- NLSP 243.8M
- PRPO 9.5M
- IPO Year
- NLSP 2021
- PRPO N/A
- Fundamental
- Price
- NLSP $4.96
- PRPO $6.59
- Analyst Decision
- NLSP
- PRPO
- Analyst Count
- NLSP 0
- PRPO 0
- Target Price
- NLSP N/A
- PRPO N/A
- AVG Volume (30 Days)
- NLSP 34.6K
- PRPO 7.9K
- Earning Date
- NLSP 11-01-2024
- PRPO 11-11-2024
- Dividend Yield
- NLSP N/A
- PRPO N/A
- EPS Growth
- NLSP N/A
- PRPO N/A
- EPS
- NLSP N/A
- PRPO N/A
- Revenue
- NLSP N/A
- PRPO $16,719,999.00
- Revenue This Year
- NLSP N/A
- PRPO $75.18
- Revenue Next Year
- NLSP N/A
- PRPO N/A
- P/E Ratio
- NLSP N/A
- PRPO N/A
- Revenue Growth
- NLSP N/A
- PRPO 52.61
- 52 Week Low
- NLSP $4.08
- PRPO $4.31
- 52 Week High
- NLSP $29.68
- PRPO $8.99
- Technical
- Relative Strength Index (RSI)
- NLSP 46.37
- PRPO 52.82
- Support Level
- NLSP $4.52
- PRPO $6.42
- Resistance Level
- NLSP $5.64
- PRPO $6.99
- Average True Range (ATR)
- NLSP 0.48
- PRPO 0.33
- MACD
- NLSP 0.07
- PRPO -0.04
- Stochastic Oscillator
- NLSP 55.44
- PRPO 69.91
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.